Despite strong evidence of effectiveness, colorectal cancer (CRC) screening remains
underused. Currently, there are several options for CRC screening, each with its own …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

DNA methylation is an epigenetic mechanism regulating gene expression. Changes in DNA
methylation were suggested to be useful biomarkers for diagnosis, and for the determination …

Colorectal cancer (CRC) is one of the most common malignancies and is a major cause of
cancer-related deaths worldwide. Thus, there is a clinical need to improve early detection of …

Liquid biopsy assays for minimal residual disease (MRD) are used to monitor and inform
oncological treatment and predict the risk of relapse in cancer patients. To-date, most MRD …

Simple Summary High-performance, non-invasive screening is a requirement in colorectal
cancer (CRC) as early detection is a key in reducing disease-related mortality in CRC …

Background: Most recurrences of early-stage colorectal cancer detected with current
surveillance measures are widespread and incurable. Circulating tumor DNA (ctDNA) may …

Simple Summary For effective cancer treatment, it is important to scrutinize individual driver
gene mutations. In this study, we investigated whether analyzing gene mutations in primary …

Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed
method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has …

Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely
identification is critical for patient survival. Detecting CRC‐associated mutations in patient …